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Background: Monitoring hepatitis C virus (HCV) inci-
dence is important for assessing intervention impact. 
Longitudinal studies of people who inject drugs 
(PWID), using repeated biological tests, are costly; 
alternatively, incidence can be estimated using bio-
logical markers of recent infection in cross-sectional 
studies. Aim: We aimed to compare incidence esti-
mates obtained from two different biological mark-
ers of recent infection in a cross-sectional study to 
inform monitoring approaches for HCV elimination 
strategies. Method: Samples from an unlinked anony-
mous bio-behavioural survey of PWID were tested for 
two recent infection markers: HCV RNA with anti-HCV 
negative (‘RNA’) and low-avidity anti-HCV with HCV 
RNA present (‘avidity’). These two markers were used 
separately and in combination to estimate HCV inci-
dence. Results: Between 2011 and 2013, 2,816 anti-
HIV-negative PWID (25% female) who had injected 
during the preceding year were either HCV-negative 
or had one of the two markers of recent infection: 57 
(2.0%) had the RNA marker and 90 (3.2%) the avidity 
marker. The two markers had similar distributions of 
risk and demographic factors. Pooled estimated inci-
dence was 12.3 per 100 person-years (pyrs) (95% cred-
ible interval: 8.8–17.0) and not significantly different 
to avidity-only (p = 0.865) and RNA-only (p = 0.691) 
estimates. However, the RNA marker is limited by its 
short duration before anti-HCV seroconversion and 
the avidity marker by uncertainty around its duration. 
Conclusion: Both markers have utility in monitoring 
HCV incidence among PWID. When HCV transmission 
is high, one marker may provide an accurate estimate 
of incidence; when it is low or decreasing, a combina-
tion may be required.
Introduction
In high-income countries, hepatitis C virus (HCV) trans-
mission is focused among people who inject drugs 
(PWID), with infection often acquired soon after initia-
tion to injecting [1,2]. In the United Kingdom (UK), it is 
estimated that around half of PWID have been infected 
with HCV [3], although there is considerable geographi-
cal variation in prevalence [4]. Estimates of HCV inci-
dence among PWID are high, typically between 10 and 
20 infections per 100 person-years (pyrs) of exposure 
[5].
Measuring incidence, and how this changes over time, 
is important for assessing the impact of interventions 
to prevent and control HCV, such as needle and syringe 
programmes (NSPs), opioid substitution therapy (OST) 
and HCV treatment as prevention (HCV TasP), as well 
as monitoring progress towards the global goal of 
eliminating HCV as a major public health threat [6]. 
Incidence is traditionally estimated through longitu-
dinal follow-up studies; however, such studies are 
expensive and difficult among PWID because follow-up 
is hindered by the illicit nature of drug use and the mar-
ginalisation of PWID [7]. An alternative approach is to 
use biological markers of recent infection in cross-sec-
tional studies. Two approaches have been advocated.
The first approach involves the detection of HCV RNA 
among individuals found to be HCV antibody (anti-
HCV)-negative, indicating an acute and therefore 
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incident infection [8]. Although evidence indicates the 
possibility of some misclassification [9,10], the length 
of time that someone remains in this state after infec-
tion (the ‘window period’) is short (< 2 months [9,11,12]) 
and therefore large sample sizes are needed unless 
incidence is very high.
The second approach is antibody avidity [13,14], an 
approach that has been used with some success for HIV 
and acute hepatitis B infections [15,16]. Samples with 
low avidity anti-HCV are typically indicative of a recent 
primary infection. The distribution of the window period 
has been assessed in panels of HCV-infected individu-
als with a known seroconversion date. Unfortunately, 
there is uncertainty surrounding the duration of the 
low-avidity period, with available evidence suggest-
ing it is between 2 and 6 months [17-19]. In addition, 
some individuals may continue to have weak avidity 
even when the infection is fully established, as dem-
onstrated for HIV [20], or if antibody titre wanes fol-
lowing spontaneous clearance. Consequently, without 
appropriate safeguards to exclude cleared infections, 
the avidity marker may suffer from lower specificity 
because of false positives.
Both these cross-sectional approaches, as well as 
cohort-based studies, have been used to measure HCV 
incidence among PWID in the UK. Two cohort studies 
suggested considerable variation in incidence from 
nine per 100 pyrs in South Wales (2004–06) [21] to 42 
per 100 pyrs among young PWID in London (2001–02) 
[22]. Studies examining HCV RNA positivity among 
anti-HCV-negative PWID produced a similar range of 
estimates (three to 40 per 100 pyrs) in different cities 
[7], while a further study using anti-HCV avidity test-
ing indicated that incidence was between four and 
12 infections per 100 pyrs across the UK (excluding 
Scotland) [13]. The marked difference in these UK esti-
mates of HCV incidence among PWID may reflect the 
fact that studies were undertaken at different times, at 
a range of locations and/or in populations engaging in 
different risks, as well as the different incidence meas-
ures used.
In order to better understand the determinants under-
lying the variation in HCV incidence among PWID, we 
undertook an analysis to compare the estimated inci-
dence, and associated risk factors, for the two different 
approaches of estimating incidence using biological 
markers (HCV RNA in antibody-negative individuals 
and antibody avidity in antibody-positive individuals 
with HCV RNA) using pooled data from a large national 
bio-behavioural survey. We also estimate overall inci-
dence based on the two approaches accounting for the 
uncertainty in their window periods. The findings are 
important for informing the choice of optimal method 
for monitoring HCV incidence among PWID in the UK 
and elsewhere.
 
Methods
Survey
PWID across England, Wales and Northern Ireland 
are recruited into an annual cross-sectional, unlinked 
anonymous bio-behavioural survey (the UAM Survey); 
methodological details have been previously reported 
[23,24]. In brief, people who have ever injected drugs 
are recruited through specialist services for PWID 
providing advice, NSPs, OST or addiction treatment. 
Service selection reflects the range of services pro-
vided for PWID and what is known about geographic 
variations in drug use. Those agreeing to participate 
self-complete a short questionnaire and provide a 
dried-blood spot (DBS) sample at the collaborating ser-
vice. DBS collection involves obtaining a few drops of 
blood, through a lancet prick to the finger, onto absor-
bent filter paper (PerkinElmer 226). The survey has 
multi-site ethical approval.
In addition to core demographics (age and gender), the 
questionnaire collects self-reported behavioural data, 
including prior imprisonment and homelessness, types 
of psychoactive drug used, injecting risks, uptake of 
health services (e.g. OST), and sexual behaviours (e.g. 
condom use). In this study, we included only individu-
als recruited between 2011 and 2013 inclusive who had 
injected during the year preceding survey participation.
Testing for recent infection markers
The DBS samples were tested for antibodies to HIV 
(anti-HIV), hepatitis C (anti-HCV) and hepatitis B core 
antibody (anti-HBc). All laboratory testing was carried 
out at the Virus Reference Department at Public Health 
England, Colindale, using previously reported methods 
[8,13]. Two methods were applied to identify recent 
infections: anti-HCV avidity testing algorithm (upon 
receipt at laboratory) and RNA testing of the anti-HCV 
negative samples (on stored samples, with testing 
undertaken during 2014–15). A 6 mm spot was used for 
serological and molecular testing.
Anti-HCV avidity testing
The method was undertaken as previously described 
[13,18]. Briefly, each sample is tested in duplicate 
Figure 1
Classification of hepatitis C virus infection status 
according to RNA and antibody positivity and avidity 
index of antibody test
Uninfected Established
infection
RNA
RNA-positive,
antibody-negative
(51–75 days)
Avidity
HCV antibodies
with weak avidity 
(60–180 days)
HCV: hepatitis C virus.
Average durations for remaining in recent infection state (the 
‘window periods’) are shown in parentheses.
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with one well incubated with urea (avidity well) and 
the second with wash buffer (control well). In the 
presence of urea, low-avidity (weakly bound) anti-
bodies will dissociate from HCV antigen bound to the 
solid phase. An avidity index (AI) is determined for 
each specimen ((optical density (OD) urea-treated/OD 
untreated) × 100), with an AI ≤ 40% considered to be 
low. As low avidity antibody can also be found in indi-
viduals who have cleared HCV RNA, specimens with 
low AI were subsequently tested for HCV RNA using 
PCR [13]. Those individuals with DBS containing both 
low-avidity anti-HCV and HCV RNA were considered to 
have recently acquired their HCV infection (i.e. to have 
markers compatible with recent primary infection).
HCV RNA testing of those anti-HCV-negative
To identify those participants whose samples were 
anti-HCV-negative and HCV RNA-positive, stored resid-
ual DBS samples from those found to be anti-HCV-neg-
ative when tested on receipt underwent retrospective 
HCV RNA testing.
Table 1
Markers of recent hepatitis C infectiona according to survey year, demographics and risk factor variables, among people who 
inject drugs, England, Wales and Northern Ireland, 2011–13 (n = 2,816)
Variable Category N
Combined markers of 
recent infection
RNA marker of recent 
infection
Avidity marker of 
recent infection
 Positive % Positive % Positive %
Year
2011 791 33 4.2 15 1.9 18 2.3
2012 969 58 6.0 18 1.9 40 4.1
2013 1,056 56 5.3 24 2.3 32 3.0
Age
<30 957 56 5.9 29 3.0 27 2.8
30–39 1,277 62 4.9 19 1.5 43 3.4
≥40 582 29 5.0 9 1.5 20 3.4
Gender
Male 2,099 101 4.8 38 1.8 63 3.0
Female 717 46 6.4 19 2.6 27 3.8
Regional prevalence
Low (<40%) 1,114 50 4.5 26 2.3 24 2.2
Medium (40–55%) 768 35 4.6 11 1.4 24 3.1
High (>55%) 934 62 6.6 20 2.1 42 4.5
Injecting duration
<1 year 157 9 5.7 3 1.9 6 3.8
1–5 years 783 39 5.0 24 3.1 15 1.9
6–10 years 591 36 6.1 12 2.0 24 4.1
11–14 years 499 22 4.4 7 1.4 15 3.0
15–19 years 457 20 4.4 7 1.5 13 2.8
≥20 years 329 21 6.4 4 1.2 17 5.2
Homelessness
Never 696 23 3.3 11 1.6 12 1.7
Yes, not past year 1,063 58 5.4 24 2.3 34 3.2
Yes, past year 1,007 65 6.5 22 2.2 43 4.3
Imprisonment
Never 1,129 54 4.8 22 1.9 32 2.8
1–4 times 886 33 3.7 14 1.6 19 2.1
≥5 times 801 60 7.5 21 2.6 39 4.9
Crack injecting
No 2,268 87 3.8 37 1.6 50 2.2
Yes 548 60 10.9 20 3.6 40 7.3
Speed (amphetamine) injecting
No 2,335 127 5.4 49 2.1 78 3.3
Yes 481 20 4.2 8 1.7 12 2.5
NSP use
Never/not in past 
year 499 25 5.0 9 1.8 16 3.2
In past year 2,300 121 5.3 48 2.1 73 3.2
Injecting and sharing past month
Did not inject past 
month 674 18 2.7 10 1.5 8 1.2
Injected and did not 
share 1,418 59 4.2 21 1.5 38 2.7
Injected and shared 724 70 9.7 26 3.6 44 6.1
NSP: needle and syringe programmes.
a Antibody-negative with RNA and weak avidity of antibody.
4 www.eurosurveillance.org
Table 2a
Univariable model results from multinomial logistic model of markers of recent infectiona and logistic regression model of 
combined outcome, among people who inject drugs, England, Wales and Northern Ireland, 2011–13 (n = 2,816)
Variable Category
Logistic model Multinomial logistic model
Combined OR 
 
(95% CI)
p value
RNA RRR 
 
(95% CI)
p value
Avidity RRR 
 
(95% CI)
p value p value diffb
Year
2011 1 (ref)
0.235
1 (ref)
0.775
1 (ref)
0.088 0.293
2012
1.46  
 
(0.94–2.27)
1.00  
 
(0.50–1.99)
1.85  
 
(1.05–3.25)
2013
1.29  
 
(0.83–2.00)
1.21  
 
(0.63–2.33)
1.35  
 
(0.75–2.42)
Age
<30
1.22  
 
(0.84–1.77)
0.555
2.06  
 
(1.15–3.69)
0.030
0.85  
 
(0.52–1.38)
0.757 0.04230–39 1 (ref) 1 (ref) 1 (ref)
≥40
1.03  
 
(0.65–1.62)
1.04  
 
(0.47–2.31)
1.02  
 
(0.60–1.75)
Gender
Male 1 (ref)
0.097
1 (ref)
0.162
1 (ref)
0.298 0.671
Female
1.36  
 
(0.95–1.94)
1.49  
 
(0.85–2.60)
1.28  
 
(0.81–2.02)
Regional prevalence
Low (<40%)
0.98  
 
(0.63–1.53)
0.060
1.63  
 
(0.80–3.32)
0.388
0.69  
 
(0.39–1.22)
0.013 0.064Medium (40–55%) 1 (ref) 1 (ref) 1 (ref)
High (>55%)
1.49  
 
(0.97–2.28)
1.53  
 
(0.73–3.21)
1.47  
 
(0.88–2.45)
Injecting duration
<1 year
0.94  
 
(0.44–1.99)
0.657
0.94  
 
(0.26–3.37)
0.277
0.94  
 
(0.38–2.34)
0.092 0.032
1–5 years
0.81  
 
(0.51–1.29)
1.49  
 
(0.74–3.01)
0.47  
 
(0.24–0.90)
6–10 years 1 (ref) 1 (ref) 1 (ref)
11–14 years
0.71  
 
(0.41–1.23)
0.68  
 
(0.27–1.74)
0.73  
 
(0.38–1.40)
15–19 years
0.71  
 
(0.40–1.24)
0.74  
 
(0.29–1.90)
0.69  
 
(0.35–1.37)
≥20 years
1.05  
 
(0.60–1.83)
0.60  
 
(0.19–1.88)
1.28  
 
(0.68–2.41)
Homelessness
Never 1 (ref)
0.018
1 (ref)
0.552
1 (ref)
0.016 0.448
Yes, not past year
1.69  
 
(1.03–2.76)
1.46  
 
(0.71–3.00)
1.90  
 
(0.98–3.69)
Yes, past year
2.02  
 
(1.24–3.28)
1.43  
 
(0.69–2.97)
2.56  
 
(1.34–4.89)
CI: Confidence interval; OR: odds ratio; ref: reference value; RRR: relative risk ratio.
a RNA-positive antibody-negative (RNA marker) and antibody-positive with weak avidity (avidity marker).
b p value diff is the p value for the effect estimates for RNA and avidity being the same.
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RNA testing involved elution from the DBS by incubat-
ing the 6 mm spot for 2 hours at 56 °C with 20 µL of 
proteinase K and 300 µL of ATL lysis buffer (Qiagen 
products: 19133 and 19076). The entire eluate was 
extracted on the Qiagen Biorobot MDX platform using 
the QIAamp One-For-All Nucleic Acid Kit (Qiagen prod-
uct: 965672) and One For All MDx cV70a protocol. 
Brome mosaic virus (BMV) was added as the internal 
control. Amplification and detection of HCV RNA and 
BMV was undertaken as previously described [25], 
employing a PCR targeting the non-coding region of the 
HCV genome.
These two approaches identified those recently 
infected at two different stages, which are mutually 
exclusive, in the sequence from being uninfected to 
having established infection (Figure 1). 
Samples that were anti-HIV positive (n = 25) were 
excluded, as the effects of HIV on the immune system 
is likely to affect anti-HCV avidity [20]. Recent HCV 
infection status was based on the two markers, (i) RNA-
positive antibody-negative (henceforth ‘RNA’), and (ii) 
HCV antibodies with weak avidity in those with HCV 
RNA (henceforth ‘avidity’). The analytical dataset con-
sisted of individuals who had one of these two mark-
ers of recent infection or who were susceptible to HCV 
infection (uninfected, defined as anti-HCV- and RNA-
negative); i.e. those with established infection were 
excluded. Analysing such data via logistic regression-
type models will therefore provide odds ratios (OR) for 
recent infection according to the two markers.
Statistical analysis
Patterns of recent infection were examined according 
to a number of demographic, geographic and risk fac-
tor covariates. The demographic variables were year 
of test (2012 and 2013 vs 2011), age (<30 and ≥40 vs 
30–39) and gender (female vs male). The geographic 
variable was regional prevalence groups that were 
Variable Category
Logistic model Multinomial logistic model
Combined OR 
 
(95% CI)
p value
RNA RRR 
 
(95% CI)
p value
Avidity RRR 
 
(95% CI)
p value p value diffb
Imprisonment
Never 1 (ref)
0.002
1 (ref)
0.272
1 (ref)
0.005 0.729
1–4 times
0.77  
 
(0.49–1.20)
0.80  
 
(0.41–1.58)
0.75  
 
(0.42–1.33)
≥5 times
1.61  
 
(1.10–2.36)
1.38  
 
(0.76–2.54)
1.77  
 
(1.1– 2.85)
Crack injecting
No 1 (ref)
< 0.001
1 (ref)
0.020
1 (ref)
0.001 0.727
Yes
2.44  
 
(1.58–3.78)
2.23  
 
(1.13–4.37)
2.60  
 
(1.48–4.56)
Speed (amphetamine) 
injecting
No 1 (ref)
0.279
1 (ref)
0.460
1 (ref)
0.417 0.962
Yes
0.76  
 
(0.47–1.24)
0.75  
 
(0.36–1.60)
0.77  
 
(0.41–1.44)
NSP use
Never/not in past year 1 (ref)
0.819
1 (ref)
0.685
1 (ref)
0.979 0.732
In past year
1.05  
 
(0.68–1.64)
1.16  
 
(0.57–2.38)
0.99  
 
(0.57–1.72)
Injecting and sharing past 
month
Did not inject past 
month 1 (ref)
< 0.001
1 (ref)
0.002
1 (ref)
< 0.001 0.304
Injected and did not 
share
1.58  
 
(0.93–2.70)
1.01  
 
(0.47–2.16)
2.29  
 
(1.06–4.94)
Injected and shared
3.90 
 
(2.30–6.62)
2.61 
 
(1.25–5.45)
5.52 
 
(2.58–11.81
CI: Confidence interval; NSP: needle and syringe programmes; OR: odds ratio; ref: reference value; RRR: relative risk ratio.
a RNA-positive antibody-negative (RNA marker) and antibody-positive with weak avidity (avidity marker).
b p value diff is the p value for the effect estimates for RNA and avidity being the same.
Table 2b
Univariable model results from multinomial logistic model of markers of recent infectiona and logistic regression model of 
combined outcome, among people who inject drugs, England, Wales and Northern Ireland, 2011–13 (n = 2,816)
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based on overall HCV antibody prevalence from 2011 
to 2013, with low defined as <40% (South West, North 
East, Wales and Northern Ireland); medium as 40–55% 
(East of England, West Midlands, East Midlands) 
and high as >55% (London, North West, South East, 
Yorkshire and the Humber). The risk factor variables 
were years since first injection (<1, 1–5, 11–14, 15–19 
and ≥20 vs 6–10), homelessness (‘yes, not in past year’ 
and ‘yes, in past year’ vs never), imprisonment (1–4 
times and 5 or more times vs never), injecting crack 
in the past month (yes vs no/did not inject in past 
month/unknown), injecting speed in the past month 
(yes vs no/did not inject in past month/unknown) 
and injecting and equipment sharing behaviour in 
the past month (derived from two sequential ques-
tions). The latter group was defined as  did not inject 
in past month, injected in past month but did not share 
equipment, and injected and shared equipment in past 
month,  and therefore incorporates the difference in 
risk between those that injected in the past month and 
those that did not.
A combined outcome for recent infection according 
to either the RNA or avidity measure was examined 
in relation to the factors above via logistic regression 
to estimate ORs for any marker of recent infection vs 
susceptible. In addition, the RNA and avidity measures 
of recent infection were each analysed as distinct out-
comes (vs those susceptible) in a multinomial logistic 
model; this allowed the effect of the covariate for the 
separate outcomes to be modelled in terms of rela-
tive risk ratios (RRR). The multinomial model allowed 
for testing the equivalence of parameters in the model 
for the two recent infection markers, i.e. whether the 
two markers provided consistent estimates of the risk 
factors that are predictive of recent infection. In this 
context, RRRs and ORs are comparable; in particular, 
if RRRs for the two markers are identical they will be 
exactly equal to the OR for the combined outcome.
Univariable analyses were conducted and a multivari-
able model constructed on the basis of backwards 
stepwise variable selection with a p value of 0.2 for 
removal. Variables were selected for the logistic and 
multinomial logistic models and any variables retained 
in either model were included in the final set of vari-
ables. Analyses were conducted using Stata version 
13.1 (StataCorp, College Station, Texas, United States).
We estimated incidence based on markers of recent 
infection using the formula: I = r/wn,
where I is the incidence rate, w the length of the window 
period, r  the number of individuals with the marker of 
recent infection and  n  the number not infected [26]. 
The uncertainty arising from both sampling variability 
of the binomial data (r, n) and the length of the win-
dow period were accounted for using a fully Bayesian 
approach. We specified uniform priors for the window 
period, ranging from 51 to 75 days for RNA and from 60 
to 180 days for avidity. For the latter, we also exam-
ined a semi-informative beta(2,2) distribution across 
the range of the 60–180 day window period, such that 
the interquartile range of the prior distribution was 
99–141 days compared with 90–150 under a uniform 
prior. Medians of the posterior distributions were taken 
as point estimates and the 2.5th and 97.5th percentiles 
as 95% credible intervals (CrI). The model was imple-
mented in WinBUGS version 1.4.3 (Medical Research 
Council, UK).
Results
Between 2011 and 2013, there were 2,816 anti-HIV neg-
ative participants who had injected during the preced-
ing year whose samples were either anti-HCV-negative 
or had one of the two markers of a probable recent HCV 
infection. Of these, 57 (2.0%) were HCV RNA-positive 
and anti-HCV-negative (‘RNA’) and a further 90 (3.2%) 
Figure 2
Univariable model results from multinomial logistic 
models of two markers of recent hepatitis C infectiona 
and logistic regression model for them combined, among 
people who inject drugs, England, Wales and Northern 
Ireland, 2011–13 (n = 2,816)
 
Year 2011
Year 2012
Year 2013
Age <30
Age 30-39
Age ≥40
Male
Female
Low-prevalence regions (<35%)
Medium-prevalence regions (35-45%)
High-prevalence regions  (>45%)
Injected <1 year
Injected 1-5 years
Injected 6-10 years
Injected 11-14 years
Injected 15-19 years
Injected ≥20 years
Never homeless
Been homeless but not in last year
Homeless in last year
Never imprisoned
Prison 1–4 times
Prison ≥5 times
Not injected crack
Injected crack
Not injected speed
Injected speed
NSP: never/not in past year
NSP: in last year
Did not inject in past month
Not shared in last month
Shared injection equipment last month
.2 .3 .5 .7 1 1.5 2 3 5 10
Odds/relative risk ratios
RNA Avidity Combined
NSP: needle and syringe programmes.
a Antibody-negative with RNA (RNA marker) and weak-avidity 
antibody (avidity marker).
95% confidence intervals are indicated by solid and dashed lines.
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had weak anti-HCV avidity in the presence of HCV RNA 
(‘avidity’). Overall, the mean age of the participants 
was 34 years (median: 34; interquartile range: 28–39) 
and 717 (25%) were female. Table 1 shows numbers of 
individuals with each marker of infection according to 
survey year, demographics and risk factor variables.
Associations between risk factors and markers 
of recent infection
The univariable results from the model (Table 2) are 
summarised in  Figure 2. Year of test and gender were 
not associated with either measure of incidence. There 
was evidence of an association (p = 0.03) with age 
for the RNA marker, with risk highest in those younger 
than 30 years, but there was no association for the 
avidity marker (p = 0.042 for inconsistency). There was 
some evidence of increased risk of recent infection 
for both markers in high-prevalence areas (OR = 1.49; 
95% confidence interval (CI): 0.97–2.28; two markers 
combined).
Patterns of recent infection were inconsistent accord-
ing to the two markers for injecting duration (p = 0.032 
for inconsistency). For the RNA marker, there was a 
slightly higher rate in those injecting for 1 to 5 years 
vs 6 to 10 years (RRR = 1.49; 95% CI: 0.74–3.01), longer 
durations had non-significant lower rates. For the avid-
ity marker, there were significantly lower rates for 1 
to 5 years injecting vs 6 to 10 years (RRR = 0.47; 95% 
CI: 0.24–0.90) and a non-significant small increase 
for injecting for more than 20 years. For both markers, 
there was no evidence of a difference in risk for those 
injecting for less than 1 year.
Homelessness, being imprisoned five or more times 
and injecting crack all showed a higher risk of recent 
HCV infection, with consistent estimates for the two 
markers. Injecting in the past month showed a mod-
est increase in risk, with a significant association for 
the avidity marker but not the RNA marker, although 
overall differences for the two markers again had non-
significant p values for inconsistency. Sharing injecting 
equipment in the past month showed a large increase 
in risk for both markers of recent HCV infection.
The stepwise selection procedure included gender, 
region, injecting duration, homelessness, imprison-
ment, crack injecting and injected/shared injecting 
equipment in the past month in the final model (Figure 
3 and Table 3). The ORs and RRRs were generally similar 
to the univariable results (Table 2), but risk factors with 
stronger associations were attenuated somewhat, such 
as homelessness (adjusted odds ratio (AOR) = 1.52 vs 
OR = 2.02 for homeless in last year, two markers com-
bined) and sharing injecting equipment in the past 
month (AOR = 2.69 vs OR = 3.90, two markers com-
bined). Interestingly, gender showed some evidence of 
an association in the adjusted model (AOR = 1.59; 95% 
CI: 1.07–2.37, two markers combined) but not in the 
univariable models.
Estimated incidence
The pooled estimate of incidence from the Bayesian 
model was 12.3 per 100 pyrs (95% CrI: 8.8–17.0) when 
using both markers of recent infection. As expected, 
the posterior distribution for the window period of RNA 
was near identical to the prior, i.e. uniformly distributed 
between 51 and 75 days. However, the posterior distri-
bution for the weak-avidity window was shifted some-
what from the prior distribution to be consistent with 
the RNA marker data, with a median duration of 100 
days (vs a mid-point of 120 days) and a 95% CrI of 68 to 
148 days. Using RNA alone gave an incidence estimate 
of 12.7 per 100 pyrs (95% CrI: 9.1–17.7), very similar to 
the pooled estimate (p value for difference = 0.891). 
Using the avidity marker alone gave an incidence esti-
mate of 11.8 per 100 pyrs (95% CrI: 6.6–21.3); this was 
imprecise owing to the uncertainty about the dura-
tion of the low-avidity period. With a semi-informative 
Figure 3
Multivariable model results from multinomial logistic 
model of markers of recent infectiona and logistic 
regression model of combined outcome, among people 
who inject drugs, England, Wales and Northern Ireland, 
2011–13 (n = 2,816)
Male
Female
Low-prevalence regions (<35%)
Medium-prevalence regions (35-45%)
High-prevalence regions (>45%)
Injected  <1 year
Injected  1–5 years
Injected  6–10 years
Injected  11–14 years
Injected  15–19 years
Injected  ≥20 years
Never imprisoned
Prison 1–4 times
Prison ≥5 times
Not injected crack
Injected crack
Did not inject in past month
Not shared in last month
Shared injection equipment last month
Never homeless
Been homeless but not in last year
Homeless in last year
.2 .3 .5 .7 1 1.5 2 3 5 10
Odds/relative risk ratios
RNA Avidity Combined
aRNA positive antibody negative (RNA marker) and antibody 
positive with weak avidity (avidity marker).
95% confidence intervals are indicated by solid and dashed lines.
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Table 3
Multivariable model results from multinomial logistic model of markers of recent infectiona and logistic regression model of 
combined outcome, among people who inject drugs, England, Wales and Northern Ireland, 2011–13 (n = 2,816)
Variable Category
Logistic model Multinomial logistic model
Combined OR  
 
(95% CI)
p value
RNA RRR 
 
(95% CI)
p value
Avidity RRR 
 
(95% CI)
p value p value diffb
Gender
Male 1 (ref)
0.022
1 (ref)
0.152
1 (ref)
0.072 0.962
Female
1.59  
 
(1.07–2.37)
1.55  
 
(0.85–2.84)
1.61  
 
(0.97–2.68)
Regional prevalence
Low (<40%)
1.08  
 
(0.69–1.71)
0.237
1.73  
 
(0.83–3.57)
0.339
0.77  
 
(0.42–1.38)
0.086 0.104Medium (40–55%) 1 (ref) 1 (ref) 1 (ref)
High (>55%)
1.41  
 
(0.91–2.18)
1.45  
 
(0.68–3.06)
1.40  
 
(0.83–2.37)
Injecting durationc
<1 year
1.00  
 
(0.46–2.16)
0.790
1.01  
 
(0.28–3.68)
0.309
0.99  
 
(0.38–2.53)
0.129 0.032
1–5 years
0.85  
 
(0.52–1.38)
1.53  
 
(0.75–3.12)
0.49  
 
(0.25–0.96)
6–10 years 1 (ref) 1 (ref) 1 (ref)
11–14 years
0.74  
 
(0.42–1.29)
0.68  
 
(0.26–1.75)
0.77  
 
(0.39–1.51)
15–19 years
0.77  
 
(0.43–1.38)
0.78 
 
(0.30–2.02)
0.77  
 
(0.38–1.57)
≥20 years
1.09  
 
(0.61–1.93)
0.61  
 
(0.19–1.92)
1.34  
 
(0.69–2.61)
Homelessness
Never 1 (ref)
0.237
1 (ref)
0.631
1 (ref)
0.103 0.234
Yes, not past year
1.49  
 
(0.89–2.48)
1.38  
 
(0.66–2.91)
1.61  
 
(0.81–3.20)
Yes, past year
1.52  
 
(0.92–2.51)
1.11  
 
(0.52–2.36)
1.90  
 
(0.97–3.71)
Imprisonment
Never 1 (ref)
0.003
1 (ref)
0.122
1 (ref)
0.019 0.974
1–4 times
0.76  
 
(0.48–1.20)
0.80  
 
(0.40–1.61)
0.74  
 
(0.41–1.35)
≥5 times
1.62  
 
(1.06–2.48)
1.63  
 
(0.83–3.17)
1.65  
 
(0.96–2.81)
Crack injecting
No 1 (ref)
< 0.001
1 (ref)
0.009
1 (ref)
< 0.001 0.949
Yes
2.32  
 
(1.58–3.41)
2.28  
 
(1.22–4.24)
2.32  
 
(1.45–3.72)
Injecting and sharing 
past month
Did not inject past month 1 (ref)
< 0.001
1 (ref)
0.036
1 (ref)
< 0.001 0.438
Injected and did not share
1.20  
 
(0.68–2.10)
0.86  
 
(0.39–1.89)
1.61  
 
(0.73–3.59)
Injected and shared
2.69  
 
(1.52–4.73)
1.83  
 
(0.83–4.06)
3.79  
 
(1.69–8.50)
CI: 95% confidence interval; OR: odds ratio; ref: reference value; RRR: relative risk ratio.
a RNA-positive antibody-negative (RNA marker) and antibody-positive with weak avidity (avidity marker).
b p value diff is the p value for the effect estimates for RNA and avidity being the same.
c Using three duration categories 0–5, 6–14 and ≥15 years, with 6–14 years as baseline, the pattern is similar. For the 0–5 years category for 
RNA, RRR = 1.64 (95% CI: 0.91–2.98) and for avidity, RRR = 0.80 (95% CI: 0.38–1.70). For the ≥15 years category for the RNA, RRR = 0.62 (95% 
CI: 0.36–1.07) and for avidity, RRR = 1.07 (95% CI: 0.66–1.73).
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beta distribution for the window period, the estimate 
was 11.1 per 100 pyrs (95% CrI: 7.0–18.9), a modest 
improvement in precision; this made no difference in 
the combined model. The avidity-only estimate (with 
informative window) was not significantly different to 
the pooled estimate (p = 0.865) or from the RNA-only 
estimate (p = 0.691).
Discussion
Our study is unique in comparing two biological mark-
ers of recent HCV infection in a large sample of com-
munity-recruited PWID. The factors associated with 
the recent infections identified by combining both 
markers, HCV RNA in those anti-HCV negative and HCV 
antibody avidity, were similar to those identified by 
each measure separately, and were generally expected 
associations with known HCV risk factors. In our com-
bined model using both markers, the avidity marker 
contributed little information on absolute incidence 
rates owing to substantial uncertainty over the win-
dow period for this measure, with the combined result 
driven by the RNA data and its more certain window 
period. Nevertheless, incidence estimates from the 
two measures were very close, and the pooled analysis 
may give a better idea of the true window period for 
weak avidity, which we estimated at around 100 days 
on average, although 95% CrI were still wide, ranging 
from 68 to 148 days.
The factors considered here in relation to recent infec-
tion were a mixture of indicators of elevated risk, such 
as frequency of imprisonment [13], and risk behaviours 
representing a recent infection risk, such as sharing 
injecting equipment [21,27,28]. We found consistent 
patterns for the two markers (and when combined), 
with factors that have previously been shown to be 
associated with increased risk of HCV infection: female 
gender [28-31], imprisonment [13,32], the injection of 
crack [22,28] and the sharing of injecting equipment 
[33,34]. Results for injecting duration showed some 
inconsistency but in general, factors that showed a 
strong association with recent infection had consistent 
results for both markers.
Previous studies of risk factors for HCV and modelling 
work, including force of infection (FOI) estimates, have 
generally indicated an increased infection risk during 
the first year of injecting [28,35], in those who started 
injecting recently [27,28] or who had been injecting for 
only a few years [36]. We did not find such an associa-
tion; however, our data are somewhat sparse, with just 
nine recent infections (i.e. having the RNA or avidity 
marker) in those injecting for less than one year; nev-
ertheless, there should be sufficient power to detect 
a threefold or higher increase in risk. It is possible 
that some respondents imprecisely recalled their age 
at first injection, which would have led to an incor-
rect time since first injection and thereby some mis-
classification of recent infections. Alternatively, high 
excess risk at initiation may largely be due to the first 
few injecting events, when the individual may not have 
learned to inject themselves or started to use services 
[37], leading to these being under-represented in our 
service based sample. While our survey approach 
is established, the illicit and marginalised nature of 
injecting drug use makes construction of a formal sam-
pling frame impossible.
The UK’s mature epidemics of injecting drug use and 
HCV have resulted in an ageing population of PWID 
with a stable HCV prevalence [38]. This could possi-
bly result in a different pattern of HCV incidence with 
time since first injection compared with that found, for 
example, in an immature injecting epidemic with many 
recent initiates or where HCV prevalence among PWID 
is very high. It is possible that re-initiation to inject-
ing after periods of cessation, for example during or 
after addiction treatment or imprisonment [39,40], 
may result in repeated short periods of elevated risk 
throughout a lifetime of injecting, similar to that which 
probably occurs at first initiation. Although this needs 
further investigation, the association with imprison-
ment, found here and previously noted [13,32], sup-
ports this possibility.
A related issue, although not significant, was that for 
the avidity marker, a higher proportion of the recent 
infections detected were among those who first 
injected more than 20 years ago (19% vs 7% for RNA). 
This might reflect misclassification bias and possibly 
be due to a small number of people with longer-term 
infections not developing HCV antibodies with high 
avidity. Reported false recency rates are less than 
1–2% in individuals without HIV [14]. However, there 
may still be issues with reduced immune response in 
those with long-term HCV infection, similar to those 
seen in individuals living with HIV [20], but related to 
other co-morbidities.
Misclassification or non-capture of recent initiates 
would be expected to reduce the number of recent 
infections observed in this group, but as the vast 
majority of participants had been injecting for longer, 
this should have a relatively small impact on the over-
all incidence. Further, this is a minor point compared 
with the uncertainty of the window periods themselves 
[8,11,17,18] and does not preclude the use of recent 
infection markers to monitor trends in incidence. 
However, further work, for example using seroconver-
sion panels, to improve understanding of the window 
periods would be helpful and is needed before routine 
clinical use of avidity testing.
Owing to the uncertainties in the window period for 
weak avidity, the combined model for incidence relied 
largely on the RNA data. Nevertheless, both markers 
have their merits: RNA is a reliable and well-understood 
marker of recent infection, but infrequently observed 
because of the short window period. The avidity-based 
marker may not be ideal for estimating absolute inci-
dence, but has greater power to detect patterns accord-
ing to risk factors or changes over time. By combining 
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both markers, we could identify risk factors for recent 
infection for which there was insufficient power – even 
in our relatively large sample – when using either 
marker alone. Future work could incorporate mark-
ers of recent infection and the FOI approach within a 
combined model. Although work is required to resolve 
a number of issues, such as the discrepancy between 
biological markers and FOI methods for injecting dura-
tion-specific risk, such modelling has the potential to 
simultaneously refine window period estimates and 
provide estimates of incidence with greater power.
The combined use of both markers of recent infection 
could reduce the need for very large sample sizes and 
costs. Power calculations using a simple simulation-
based approach [41] indicate that a survey recruiting 
annually around 1,000 participants without an estab-
lished infection, and where around 5% of these partici-
pants had one of the two markers of recent infection at 
baseline, there would be over 90% power of detecting 
a halving of incidence over 4 years, although a reduc-
tion by one third may not be detectable (56% power). If 
the RNA marker is used alone (ca 2% at baseline), only 
a reduction by two thirds would be reliably detected 
(power = 86%) and detecting a halving of incidence is 
not guaranteed (power = 54%). This is a general prob-
lem with detecting decreases in incidence as over time, 
the number of recent infections will become extremely 
low. Of course, a genuine decrease in incidence will 
also result in lower prevalence, especially in recent 
initiates to injecting; therefore a combined approach 
may be most useful for detecting the impact of TasP, 
NSP and OST, and in monitoring progress towards the 
global strategy target to reduce HCV incidence by 90% 
by 2030 [6]. However, the actual approach taken in a 
country or area will depend on the baseline hepatitis 
C incidence and the rate of decline expected. These 
approaches will usually provide a better insight into the 
extent of recent infections than data on new HCV diag-
noses, as people may have been infected some time 
before their diagnosis and changes in diagnosis rates 
may not reflect underlying incidence but rather detec-
tion rates and testing practice, e.g. following temporal 
variations in the offer and uptake of diagnostic testing. 
However, monitoring incidence using the approaches 
applied here may not be practical among those popula-
tions and groups where the overall HCV incidence and 
risks are very low; very large sample sizes would be 
needed, and combination of methods may therefore be 
required.
Conclusion
Our findings indicate that the two biological approaches 
to estimating incidence identified associations with 
similar injecting risk behaviours and social and demo-
graphic profiles. This indicates that both have utility in 
monitoring incidence, although the short-lived nature 
of the states assessed by these two markers limits the 
use of only one marker, particularly when the incidence 
is not high. Meeting the hepatitis C elimination goals 
in the Global Health Sector Strategy for Hepatitis [6], 
will require an assessment of the impact on HCV trans-
mission of interventions such as NSPs, OST and TasP 
that need to be delivered to PWID to achieve it, in the 
context of declining incidence. A robust measure of 
incidence among PWID could be provided by using the 
two biological markers examined here in combination.
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